Fresenius stock gains after confirming 2026 guidance on solid half-year figures
Published on 09/21/2026 at 11:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius SE (ISIN DE0005785604) stock is trading on Xetra at a level supported by confirmed 2026 guidance after the company reported higher revenue and earnings for the first half of 2026 on August 6, 2026. The health care group underlined its outlook for full-year revenue and earnings, giving investors fresh visibility on the business trajectory.
Half-year 2026 figures underpin Fresenius stock
According to Fresenius in its half-year report released on August 6, 2026, group revenue for the first half of 2026 rose to EUR 11.8 billion, an increase of 7.3 percent compared with EUR 11.0 billion in the first half of 2025. The company reported that net income attributable to shareholders for the same period increased to EUR 530 million, up 12.8 percent from EUR 470 million a year earlier, highlighting improved profitability alongside the top-line growth.
Operating earnings also moved higher: Fresenius stated that EBIT for the first half of 2026 reached EUR 1.34 billion, compared with EUR 1.22 billion in the first half of 2025, corresponding to growth of 9.8 percent as efficiency measures and portfolio adjustments continued to take effect. Based on these results, the company confirmed its guidance for full-year 2026, targeting low-to-mid single-digit revenue growth and a high-single-digit increase in net income compared with 2025, which provides a quantitative framework for investors assessing the stock.
Margins, debt and outlook in focus
Fresenius reported that its EBIT margin in the first half of 2026 improved to 11.4 percent from 11.1 percent in the first half of 2025, reflecting both operational improvements and ongoing cost discipline. In addition, the group continued to reduce leverage, noting that net debt stood at EUR 18.2 billion as of June 30, 2026, down from EUR 19.0 billion as of June 30, 2025, which can ease concerns about balance-sheet risk as interest rates remain an important factor for highly leveraged companies. For investors, the combination of rising earnings, a slightly higher margin and gradual debt reduction is central to the Fresenius stock story at this stage.
In its half-year communication, Fresenius reiterated that it intends to maintain a dividend policy aligned with earnings growth, having paid a dividend of EUR 0.92 per share for fiscal year 2025 and aiming to grow the distribution in line with net income over time, subject to business performance and balance-sheet priorities. While the company did not change its full-year 2026 guidance in August 2026, the confirmation itself is relevant because it signals confidence in achieving the forecast ranges against a backdrop of regulatory and reimbursement uncertainties that often affect health care providers.
Stock level and trading data
On Xetra, Fresenius stock most recently closed at EUR 28.40 as of September 18, 2026, compared with a prior close of EUR 27.85, corresponding to a daily gain of 2.0 percent at that venue. Over the past 52 weeks the shares have traded between a low of EUR 24.10 and a high of EUR 31.60, placing the latest closing price around 10.1 percent above the 52-week low and about 10.1 percent below the 52-week high, which illustrates that the stock is currently positioned in the middle of its recent range rather than at an extreme.
Fresenius stock key data
- Company: Fresenius SE
- ISIN: DE0005785604
- WKN: 578560
- Ticker: FRE
- Trading venue: Xetra
- Price (as of September 18, 2026, 05:30): 28.40 EUR
- Market capitalization: 16.0 billion EUR (as of September 18, 2026)
- Sector / Industry: Health Care / Health Care Providers and Services
- Index membership: DAX
